Crossref
First and Best Treatments for EGFR and PD-L1 - Competition for First Line Therapy in Adenocarcinoma
Oncomedicine · 2017
DOI: 10.7150/oncm.20759 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncomedicine, 2017. Verfasst von Paul Zarogoulidis und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Zarogoulidis, P., Man, Y., Hohenforst-Schmidt, W., Yarmus, L., Huang, H., Bai, C., Barbetakis, N., Kosmidis, C., Sardeli, C., Kerenidi, T., Papatsibas, G., & Tsiouda, T. (2017). First and Best Treatments for EGFR and PD-L1 - Competition for First Line Therapy in Adenocarcinoma. Oncomedicine. https://doi.org/10.7150/oncm.20759
Vancouver
Zarogoulidis P, Man Y, Hohenforst-Schmidt W, Yarmus L, Huang H, Bai C, et al. First and Best Treatments for EGFR and PD-L1 - Competition for First Line Therapy in Adenocarcinoma. Oncomedicine. 2017. doi:10.7150/oncm.20759
BibTeX
@article{Zarogoulidis2017,
author = {Zarogoulidis, Paul and Man, Yan-Gao and Hohenforst-Schmidt, Wolfgang and Yarmus, Lonny and Huang, Haidong and Bai, Chong and Barbetakis, Nikolaos and Kosmidis, Christoforos and Sardeli, Chrisanthi and Kerenidi, Theodora and Papatsibas, George and Tsiouda, Theodora},
title = {First and Best Treatments for EGFR and PD-L1 - Competition for First Line Therapy in Adenocarcinoma},
journal = {Oncomedicine},
year = {2017},
doi = {10.7150/oncm.20759}
}
EUVIMED